MENU
+Compare
ARWR
Stock ticker: NASDAQ
AS OF
Sep 16, 04:59 PM (EDT)
Price
$29.42
Change
+$0.75 (+2.62%)
Capitalization
3.96B

ARWR Arrowhead Pharmaceuticals Forecast, Technical & Fundamental Analysis

Arrowhead Pharmaceuticals Inc is an American biotechnology company... Show more

Industry: #Biotechnology
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ARWR with price predictions
Sep 15, 2025

ARWR sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for ARWR moved above the 200-day moving average on August 28, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 08, 2025. You may want to consider a long position or call options on ARWR as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ARWR just turned positive on August 08, 2025. Looking at past instances where ARWR's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

ARWR moved above its 50-day moving average on August 11, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ARWR crossed bullishly above the 50-day moving average on August 13, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARWR advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 191 cases where ARWR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ARWR moved out of overbought territory on September 15, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 22 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARWR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ARWR broke above its upper Bollinger Band on September 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARWR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.587) is normal, around the industry mean (20.594). P/E Ratio (0.000) is within average values for comparable stocks, (53.282). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.156). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (6.562) is also within normal values, averaging (342.112).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARWR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ARWR is expected to report earnings to fall 83.38% to -20 cents per share on December 01

Arrowhead Pharmaceuticals ARWR Stock Earnings Reports
Q3'25
Est.
$-0.21
Q2'25
Missed
by $0.40
Q1'25
Beat
by $3.20
Q4'24
Missed
by $1.00
Q3'24
Missed
by $0.39
The last earnings report on August 07 showed earnings per share of -125 cents, missing the estimate of -86 cents. With 747.38K shares outstanding, the current market capitalization sits at 3.96B.
A.I. Advisor
published General Information

General Information

a developer of novel drugs to treat intractable diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
177 E. Colorado Boulevard
Phone
+1 626 304-3400
Employees
525
Web
https://www.arrowheadpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PNVAX48.83N/A
N/A
Putnam International Capital Opp A
NEAGX54.60N/A
N/A
Needham Aggressive Growth Retail
DADGX19.37N/A
N/A
Dunham Small Cap Growth A
OGGFX21.46N/A
N/A
JPMorgan Small Cap Growth I
GBLAX41.13N/A
N/A
American Funds Global Balanced A

ARWR and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with DNLI. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
-3.53%
DNLI - ARWR
55%
Loosely correlated
-7.26%
IMNM - ARWR
52%
Loosely correlated
+2.93%
RGNX - ARWR
52%
Loosely correlated
-1.20%
BEAM - ARWR
52%
Loosely correlated
+3.30%
SYRE - ARWR
52%
Loosely correlated
-5.18%
More